Oral treatment with vanadium of Zucker fatty rats activates muscle glycogen synthesis and insulin-stimulated protein phosphatase-1 activity

Molecular and Cellular Biochemistry

Volumn 236, Issue 1-2, 2002, Pages 123-131

  Semiz, S ^a   McNeill, J H ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Insulin resitance; Serine threonine kinases and phosphatases; Skeletal muscle

Indexed keywords

BIS(MALTOALTO)OXOVANADIUM(IV); DRINKING WATER; GLUCOSE; GLYCOGEN; GLYCOGEN SYNTHASE; GLYCOGEN SYNTHASE KINASE 3; INSULIN; PHOSPHOPROTEIN PHOSPHATASE 1; UNCLASSIFIED DRUG; VANADIUM DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; GLUCOSE METABOLISM; GLYCOGEN MUSCLE LEVEL; GLYCOGEN SYNTHESIS; IN VIVO STUDY; INSULIN SENSITIVITY; MALE; NONHUMAN; RAT; RAT STRAIN; SKELETAL MUSCLE; STIMULUS RESPONSE;

ADMINISTRATION, ORAL; ANIMALS; GLYCOGEN; GLYCOGEN SYNTHASE; GLYCOGEN SYNTHASE KINASE 3; INSULIN; MALE; MUSCLE, SKELETAL; MUSCLES; PHOSPHOPROTEIN PHOSPHATASE; RATS; RATS, ZUCKER; TIME FACTORS; VANADIUM;

ANIMALIA;

EID: 0036329131     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016116700632     Document Type: Article

References (60)

1. Glycogen synthase and phosphofructokinase protein and mRNA levels in skeletal muscle from insulin-resistant patients with non-insulin-dependent diabetes mellitus
2. Normal insulin-dependent activation of Akt/protein kinase B, with diminished activation of phosphoinositide 3-kinase, in muscle in type 2 diabetes
3. Reduced glycogen synthase activity in skeletal muscle from obese patients with and without type 2 (non-insulin-dependent) diabetes mellitus
4. Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes
5. Insulin resistance is associated with reduced fasting and insulin-stimulated glycogen synthase phosphatase activity in human skeletal muscle
6. The molecular mechanism by which insulin stimulates glycogen synthesis in mammalian skeletal muscle
7. Analysis of the in vivo phosphorylation state of rabbit skeletal muscle glycogen synthase by fast-atom-bombardment mass spectrometry
8. The molecular mechanism by which adrenalin inhibits glycogen synthesis
9. Glycogen synthase from rabbit skeletal muscle; effect of insulin on the state of phosphorylation of the seven phosphoserine residues in vivo
10. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase
11. Inactivation of rabbit muscle glycogen synthase by glycogen synthase kinase-3. Dominant role of the phosphorylation of Ser-640 (site-3a)
12. Insulin action rapidly decreases multifunctional protein kinase activity in rat adipose tissue
13. Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B
14. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
15. Tyrosine dephosphorylation of glycogen synthase kinase-3 is involved in its extracellular signal-dependent inactivation
16. Insulin activates protein kinase B, inhibits glycogen synthase kinase-3 and activates glycogen synthase by rapamycin-insensitive pathways in skeletal muscle and adipose tissue
17. The protein phosphatases involved in cellular regulation. Evidence that dephosphorylation of glycogen phosphorylase and glycogen synthase in the glycogen and microsomal fractions of rat liver are catalysed by the same phosphatase-1
18. Glycogen synthase: Activation by insulin and effect of transgenic overexpression in skeletal muscle
19. Protein phosphatase-1 and insulin action
20. Defective insulin response of phosphorylase phosphatase in insulin-resistant humans
21. Glycogen synthase activation in the epididymal adipose tissue from chronic hyperinsulinemic/obese rats
22. Insulin increases liver protein phosphatase-1 and protein phosphatase-2C activities in lean, young adult rhesus monkeys
23. Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats
24. Oral administration of vanadate normalizes blood glucose levels in streptozotocin-treated rats. Characterization and mode of action
25. Long term improvement of glucose homeostasis by vanadate in obese hyperinsulinemic fa/ fa rats
26. Vanadate normalizes hyperglycemia in two mouse models of non-insulin-dependent diabetes mellitus
27. Acute and chronic oral administration of bis(maltolato)oxovanadium(IV) in Zucker diabetic fatty (ZDF) rats
28. Metabolic effects of sodium metavanadate in humans with insulin-dependent and noninsulin-dependent diabetes mellitus in vivo and in vitro studies
29. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus
30. Insulin sensitivity indices obtained from oral glucose tolerance testing: Comparison with the euglycemic insulin clamp
31. An insulin-stimulated ribosomal protein S6 kinase from rabbit liver
32. Mitogen-activated S6 kinase is stimulated via protein kinase C-dependent and independent pathways in Swiss 3T3 cells
33. Effects of diabetes, vanadium, and insulin on glycogen synthase activation in Wistar rats
34. In vivo regulation of protein-serine kinases by insulin in skeletal muscle of fructose-hypertensive rats
35. Insulin-mediated glycogen synthase activity in muscle of spontaneously insulin-resistant and diabetic rhesus monkeys
36. Protein phosphatase-1 and -2A activities in heart, liver, and skeletal muscle extracts from control and diabetic rats
37. An improved procedure for identifying and quantitating protein phosphatases in mammalian tissues
38. General characteristics of the insulin resistance syndrome: Prevalence and heritability. European Group for the study of Insulin Resistance (EGIR)
39. Postexercise muscle glycogen resynthesis in obese insulin-resistant Zucker rats
40. Insulin resistance in skeletal muscles in patients with NIDDM
41. Increased synthase phosphatase activity is responsible for the super-activation of glycogen synthase in hepatocytes from fasted obese Zucker rats
42. Oligo- and polysaccharide inhibition of muscle transferase D phosphatase
43. Coordinated feedback regulation of muscle glycogen metabolism: Inhibition of purified phosphorylase phosphatase by glycogen
44. Mechanism of muscle glycogen autoregulation in humans
45. Insulin control of glycogen metabolism in knockout mice lacking the muscle-specific protein phosphatase PP1G/RGL
46. Inhibition of glycogen synthase kinase-3 by insulin in cultured human skeletal muscle myoblasts
47. Increased glycogen synthase kinase-3 activity in diabetes- and obesity-prone C57BL/6J mice
48. Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes
49. The effects of glucose and the hexosamine biosynthesis pathway on glycogen synthase kinase-3 and other protein kinase that regulate glycogen synthase activity
50. Insulin-stimulated glycogen synthesis in cultured hepatoma cells: Differential effects of inhibitors of insulin signaling molecules
51. Phosphorylation of sites 3a and 3b (Ser640 and Ser644) in the control of rabbit muscle glycogen synthase
52. Multiple mechanisms for the phosphorylation of C-terminal regulatory sites in rabbit muscle glycogen synthase expressed in COS cells
53. Glycogen synthase sensitivity to insulin and glucose-6-phosphate is mediated by both NH2- and COOH-terminal phosphorylation sites
54. Regulation of glycogen synthase activation in isolated hepatocytes
55. Protein kinase Ctheta expression is increased upon differentiation of human skeletal muscle cells: Dysregulation in type 2 diabetic patients and a possible role for protein kinase Ctheta in insulin-stimulated activity
56. Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects
57. In vivo antidiabetic actions of naglivan, an organic vanadyl compound in streptozotocin-induced diabetes
58. Metabolic effects of vanadyl sulfate in humans with non-insulin-dependent diabetes mellitus: In vivo and in vitro studies
59. Mechanisms of vanadium action: Insulin-mimetic or insulin-enhancing agent?